Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on May 12, 2009
JNCI Journal of the National Cancer Institute 2009 101(10):698-699; doi:10.1093/jnci/djp098
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/10/698    most recent
djp098v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chivukula, M.
Right arrow Articles by Davidson, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chivukula, M.
Right arrow Articles by Davidson, N. E.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

EDITORIALS

Small Beginnings: Do They Matter? The Importance of Lymphovascular Invasion in Early Breast Cancer

Mamatha Chivukula, Adam Brufsky, Nancy E. Davidson

Affiliation of authors: Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

Correspondence to: Nancy E. Davidson, MD, University of Pittsburgh Cancer Institute, 5150 Centre Ave, Ste 500, UPMC Cancer Pavilion, Pittsburgh, PA 15232 (e-mail: davidsonne@upmc.edu).

The first 10% of the full text of this article appears below.

In the era of tailored therapy, the evaluation of systemic treatment of breast cancer has been increasingly dominated by consideration of biological features of the tumor and the host. Established breast cancer prognostic factors—those that determine natural history of breast cancer—include axillary nodal status, tumor size, histological grade, hormone receptor status, HER-2 expression, and presence of lymphovascular invasion. These factors often inform decisions about whether to use adjuvant systemic therapy. In contrast, predictive markers like expression of estrogen receptor (ER) alpha, progesterone receptor, and HER-2 protein are powerful tools to select certain types of therapy. Techniques to examine a myriad of genomic, transcriptional, or proteomic factors simultaneously, so-called ‘omics, currently dominate this field.

In this molecular age, it . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2009 101: 695. [Extract] [Full Text] [PDF]